Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented With Acute Myeloid Leukaemia After Smallpox Vaccination

Research Paper Title

Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented With Acute Myeloid Leukemia After Smallpox Vaccination.

Background

Smallpox vaccine is contraindicated in immunosuppression due to increased risk for adverse reactions (eg, progressive vaccinia).

The researchers describe the first-ever use of tecovirimat as a preemptive vaccinia virus treatment strategy during induction chemotherapy in an active duty service member who presented with acute leukaemia and inadvertent auto-inoculation after smallpox vaccination.

Reference

Lindholm, D.A., Fisher, R.D., Montgomery, J.R., Davidson, W., Yu, P.A., Yu, Y.C., Burgado, J., Wilkins, K., Petersen, B.W. & Okulicz, J.F. (2019) Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented With Acute Myeloid Leukemia After Smallpox Vaccination. Clinical Infectious Diseases. 69(12), pp.2205-2207. doi: 10.1093/cid/ciz286.

Advertisements

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.